OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PMINYSE$0.2263

Picard Medical, Inc.

InsuranceRules + LLM

Capital Structure and Liquidity Picard Medical, Inc. has a negative total equity of -$1.45 million and a current ratio of 0.75, indicating that current liabilities exceed current assets. The company's liquidity is assessed as high, but its cash and equivalents amount to only $121,000, which is significantly lower than its operating cash flow of -$3.8 million and free cash flow of -$3.83 million. The market cap is $16.63 million, with a market price of $0.22 per share. ## Profitability and Returns The company reported a net loss of $7.62 million for Q1 2026, with an operating loss of $4.51 million. The return on equity is 5.26%, while the return on assets is -0.68%, indicating poor asset utilization. The company's gross profit is $275,000, but this is overshadowed by its significant operating and net losses. ## Segments and Geographic Exposure Picard Medical, Inc. operates in the insurance and brokerage sector, with a focus on multiline insurance. The company's revenue is primarily concentrated in the United States, with some exposure to Europe and other foreign countries. However, the exact revenue concentration by segment and geography is not disclosed in the provided data. ## Growth Trajectory The company's revenue for Q1 2026 is $1.15 million, but it is not clear from the data whether this represents growth or a decline compared to previous periods. The company's outlook for the current and next fiscal years is not provided, but the significant net loss and negative cash flows suggest a challenging growth trajectory. ## Risk Factors The company faces several risk factors, including a going-concern issue, substantial doubt about its ability to continue as a going concern, and potential dilution from future offerings. The risk assessment indicates medium dilution potential, and the company has a high liquidity risk due to its negative equity and current liabilities exceeding current assets. ## Recent Events Recent events include the filing of a Form 10-Q for Q1 2026, which includes forward-looking statements and a discussion of various risks and uncertainties. The company has also issued convertible notes and warrants, and there are subsequent events related to the conversion of senior secured notes into common stock and the issuance of new warrants.

30-day price · PMI-0.43 (-61.7%)
Low$0.11High$0.81Close$0.26As of8 Jun, 00:00 UTC
Profile
CompanyPicard Medical, Inc.
ExchangeNYSE
TickerPMI
CIK0002030617
SICSurgical & Medical Instruments & Apparatus
SectorFinancials
BusinessInsurance
Industry groupInsurance
IndustryInsurance
AI analysis

Business. Picard Medical, Inc. (PMI) is a multiline insurance and brokers company that provides insurance products and services to clients, generating revenue primarily through premiums and fees from insurance policies and brokerage services.

Classification. Picard Medical, Inc. is classified under the Financials sector, specifically in the Insurance business sector and the Insurance industry, with a classification confidence of 0.92 based on rule-based classification.

## Capital Structure and Liquidity Picard Medical, Inc. has a negative total equity of -$1.45 million and a current ratio of 0.75, indicating that current liabilities exceed current assets. The company's liquidity is assessed as high, but its cash and equivalents amount to only $121,000, which is significantly lower than its operating cash flow of -$3.8 million and free cash flow of -$3.83 million. The market cap is $16.63 million, with a market price of $0.22 per share. ## Profitability and Returns The company reported a net loss of $7.62 million for Q1 2026, with an operating loss of $4.51 million. The return on equity is 5.26%, while the return on assets is -0.68%, indicating poor asset utilization. The company's gross profit is $275,000, but this is overshadowed by its significant operating and net losses. ## Segments and Geographic Exposure Picard Medical, Inc. operates in the insurance and brokerage sector, with a focus on multiline insurance. The company's revenue is primarily concentrated in the United States, with some exposure to Europe and other foreign countries. However, the exact revenue concentration by segment and geography is not disclosed in the provided data. ## Growth Trajectory The company's revenue for Q1 2026 is $1.15 million, but it is not clear from the data whether this represents growth or a decline compared to previous periods. The company's outlook for the current and next fiscal years is not provided, but the significant net loss and negative cash flows suggest a challenging growth trajectory. ## Risk Factors The company faces several risk factors, including a going-concern issue, substantial doubt about its ability to continue as a going concern, and potential dilution from future offerings. The risk assessment indicates medium dilution potential, and the company has a high liquidity risk due to its negative equity and current liabilities exceeding current assets. ## Recent Events Recent events include the filing of a Form 10-Q for Q1 2026, which includes forward-looking statements and a discussion of various risks and uncertainties. The company has also issued convertible notes and warrants, and there are subsequent events related to the conversion of senior secured notes into common stock and the issuance of new warrants.
Key takeaways
  • Picard Medical, Inc. has a negative total equity and a current ratio below 1, indicating significant liquidity and solvency risks.
  • The company reported a substantial net loss and operating loss for Q1 2026, with poor returns on equity and assets.
  • The company's revenue is primarily concentrated in the United States, with some exposure to Europe and other foreign countries.
  • The company faces significant risk factors, including going-concern issues, potential dilution, and regulatory and operational challenges.
  • Recent events include the issuance of convertible notes and warrants, and subsequent events related to the conversion of senior secured notes into common stock.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodQ1 2026
CurrencyUSD
Revenue$1.1M
Gross profit$275.0k
Operating income-$4.5M
Net income-$7.6M
R&D$1.9M
SG&A
D&A$46.0k
SBC$165.0k
Operating cash flow-$3.8M
CapEx$26.0k
Free cash flow-$3.8M
Total assets$11.2M
Total liabilities$12.7M
Total equity-$1.4M
Cash & equivalents$121.0k
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY2025$4.9M-$13.3M-$27.0M
FY2025$4.4M-$13.7M-$21.1M
FY2025
PeriodGross %Op %Net %FCF %
FY2025
FY2025
FY2025
PeriodAssetsEquityCashDebt
FY2025$22.5M$3.8M$7.5M
FY2025$12.1M-$44.0M$96.0k
FY2025-$23.8M
PeriodOCFCapExFCFSBC
FY2025-$15.7M$754.0k
FY2025-$11.9M$886.0k
FY2025
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
Q1 2026$1.1M-$4.5M-$7.6M-$3.8M
Q1 2026
Q3 2025$3.9M-$10.3M-$22.7M
Q2 2025$2.7M-$6.8M-$12.3M
PeriodGross %Op %Net %FCF %
Q1 2026
Q1 2026
Q3 2025
Q2 2025
PeriodAssetsEquityCashDebt
Q1 2026$11.2M-$1.4M$121.0k
Q1 2026$22.5M$3.8M$7.5M
Q3 2025$13.5M$8.0M$2.8M
Q2 2025$11.7M-$54.5M$410.0k
PeriodOCFCapExFCFSBC
Q1 2026-$3.8M$26.0k-$3.8M$165.0k
Q1 2026
Q3 2025-$11.3M$528.0k
Q2 2025-$4.8M$324.0k
Valuation
Market price$0.22
Market cap$16.6M
Enterprise value$16.5M
P/E
Reported non-GAAP P/E
EV/Revenue14.3
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$2.5M
Net cash$121.0k
Current ratio0.8
Debt/Equity-0.0
ROA-67.9%
ROE5.3%
Cash conversion50.0%
CapEx/Revenue2.3%
SBC/Revenue14.3%
Asset intensity0.0
Dilution ratio
Risk assessment
Dilution riskMedium
Liquidity riskHigh
  • Current liabilities exceed current assets.
  • Filings reference going-concern or substantial-doubt language.
  • Source documents mention dilution or offering risk.
Industry benchmarks
Activity: Multiline Insurance & Brokers · cohort 6 companies
MetricPMIActivity
Op margin-392.3%0.7% medp25 -1.3% · p75 1.2%bottom quartile
Net margin-662.3%-1.0% medp25 -166.7% · p75 3.8%bottom quartile
Gross margin23.9%23.9% medp25 22.9% · p75 34.2%above median
R&D / revenue164.8%164.8% medp25 164.8% · p75 164.8%bottom quartile
CapEx / revenue2.3%1.8% medp25 0.8% · p75 2.6%above median
Debt / equity-0.0%14.5% medp25 -291.3% · p75 44.9%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 05:56 UTC#389861da
Market quoteclose USD 0.22 · shares 0.08B diluted
no public URL
2026-05-10 05:56 UTC#69c06356
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 00:27 UTCJob: 127f05d4